MCRB Seres Therapeutics
- 0.930
- +0.013+1.41%
- 0.951
- +0.022+2.36%
Seres Therapeutics News
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer von Moltke Lisa
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Shaff Eric D.
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Young Teresa L.
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Henn Matthew R.
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Ege David S.
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer DesRosier Thomas
Seres Therapeutics | 10-Q: Quarterly report
Seres Therapeutics | 8-K: SERES THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES
Seres Therapeutics | 8-K: Current report
Seres Therapeutics | 8-K: Current report
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Dere Willard H
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Fraser Claire
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Biondi Paul
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Kender Richard N
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Graves Kurt
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Ausiello Dennis A
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Berenson Stephen
Seres Therapeutics | 8-K: Current report
Seres Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(4.5%)
Seres Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Thorell Marella
Analysis
Price Target
No Data
